OncoMatch/Clinical Trials/NCT04485013
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Is NCT04485013 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for cancer.
Treatment: TTX-080 · TTX-080 · pembrolizumab · cetuximab · FOLFIRI · cetuximab · TTX-080 — TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: investigational agent
Use of an investigational agent within 28 days prior to the first dose of study treatment and throughout the study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Arizona Oncology Associates · Tucson, Arizona
- University of Southern California · Los Angeles, California
- Hoag Memorial Hospital · Newport Beach, California
- Rocky Mountain Cancer Centers · Denver, Colorado
- Yale Cancer Center · New Haven, Connecticut
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04485013 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify